Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 30, 2026 | $0.66 | −84.8% | $2.74B | +3.4% | $3.20 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | $2.15 | +31.1% | $2.48B | +1.9% | $3.04 |
| Q4 FY25ended Dec 31, 2025 | — | −$0.33 | −118.0% | $2.28B | −7.1% | — |
| Q3 FY25ended Sep 30, 2025 | — | $3.17 | +19.2% | $2.53B | +2.8% | — |
| Q2 FY25ended Jun 30, 2025 | — | $4.33 | +8.3% | $2.65B | +7.3% | — |
| Q1 FY25ended Mar 31, 2025 | — | $1.64 | −39.3% | $2.43B | +6.1% | — |
| Q4 FY24ended Dec 31, 2024 | — | $1.83 | +7.6% | $2.45B | +2.9% | — |
| Q3 FY24ended Sep 30, 2024 | — | $2.66 | — | $2.47B | −2.5% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Biogen shares, not any token. As of Jul 30, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $4.00 | — | $2.46B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $2.70 | — | $2.29B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $1.70 | — | $2.39B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$0.47 | — | $2.53B | — | — |